Medical Technology Company Presents Dry Eye Disease Clinical Trial Results at The ASCRS

In a significant development for millions suffering from Dry Eye Disease (DED), Palatin Technologies, Inc. recently unveiled the results of their Phase 3 PL9643 MELODY-1 clinical trial at the prestigious American Society of Cataract and Refractive Surgery (ASCRS) conference in 2024. The findings mark a promising advancement in the treatment of DED, offering new hope for patients seeking relief from this chronic condition. $Palatin Technologies(PTN.US)$